Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Analyst Comment

Gubra: Præsentation af Q3 2025 (optagelse)

By Michael FriisHead of Equities
Gubra

I dag præsenterede CFO Kristian Borbos samt Investor Relations & Strategy Lead Emma Jappe Lange resultaterne for årets første 9 måneder af 2025 samt forventningerne til resten af året. Ud over de finansielle resultater var der fokus på pipelinen inden for vægttab, og især kandidaten UNC2, der har fokus på sundt vægttab gennem opretholdelse af muskelmasse, og som forventes at rykke til kliniske fase 1-forsøg i løbet af første halvdel af 2026.

Se eller gense eventet her: Q3 2025 event

Disclaimer: HC Andersen Capital modtager betaling fra Gubra på en Digital IR/Corporate Visibility aftale./Michael Friis 07/11-2025 kl. 15.00.

Gubra is a pharmaceutical company. The company's operations are focused on the early stages of drug development. They primarily conduct research and development in the area of metabolic and fibrotic diseases. The company's product portfolio includes several brands and drugs, and the operations are conducted on a global level, with the largest presence in North America and the Nordic region. The headquarters are located in Hørsholm, Denmark.

Read more on company page
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.